135 related articles for article (PubMed ID: 22978343)
1. Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
Woloch C; Di Paolo A; Marouani H; Bocci G; Ciccolini J; Lacarelle B; Danesi R; Iliadis A
Curr Top Med Chem; 2012; 12(15):1713-9. PubMed ID: 22978343
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
Bocci G; Danesi R; Di Paolo AD; Innocenti F; Allegrini G; Falcone A; Melosi A; Battistoni M; Barsanti G; Conte PF; Del Tacca M
Clin Cancer Res; 2000 Aug; 6(8):3032-7. PubMed ID: 10955781
[TBL] [Abstract][Full Text] [Related]
4. Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients.
Di Paolo A; Danesi R; Falcone A; Cionini L; Vannozzi F; Masi G; Allegrini G; Mini E; Bocci G; Conte PF; Del Tacca M
Ann Oncol; 2001 Sep; 12(9):1301-6. PubMed ID: 11697844
[TBL] [Abstract][Full Text] [Related]
5. Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Bocci G; Danesi R; Allegrini G; Innocenti F; Di Paolo A; Falcone A; Conte PF; Del Tacca M
Eur J Clin Pharmacol; 2002 Dec; 58(9):593-5. PubMed ID: 12602342
[TBL] [Abstract][Full Text] [Related]
6. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
7. Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer.
Ibrahim T; Di Paolo A; Amatori F; Mercatali L; Ravaioli E; Flamini E; Sacanna E; Del Tacca M; Danesi R; Amadori D
J Clin Pharmacol; 2012 Mar; 52(3):361-9. PubMed ID: 21383342
[TBL] [Abstract][Full Text] [Related]
8. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients.
Di Paolo A; Ibrahim T; Danesi R; Maltoni M; Vannozzi F; Flamini E; Zoli W; Amadori D; Del Tacca M
Ther Drug Monit; 2002 Oct; 24(5):588-93. PubMed ID: 12352929
[TBL] [Abstract][Full Text] [Related]
9. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
[TBL] [Abstract][Full Text] [Related]
10. Improved analysis of 5-Fluorouracil and 5,6-dihydro-5-Fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling.
Di Paolo A; Danesi R; Ciofi L; Vannozzi F; Bocci G; Lastella M; Amatori F; Martelloni BM; Ibrahim T; Amadori D; Falcone A; Del Tacca M
Ther Drug Monit; 2005 Jun; 27(3):362-8. PubMed ID: 15905808
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of tomudex combined with 5-fluorouracil plus levofolinic acid in advanced head and neck cancer and colorectal cancer.
Caponigro F; Avallone A; McLeod H; Cartenì G; De Vita F; Casaretti R; Morsman J; Blackie R; Budillon A; De Lucia L; Gravina A; Catalano G; Comella P; Comella G
Clin Cancer Res; 1999 Dec; 5(12):3948-55. PubMed ID: 10632324
[TBL] [Abstract][Full Text] [Related]
12. [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
Dong QM; He YJ; Li S; Zhou ZM; Zhang L; Zhou ZW; Xia ZJ; Li YY
Ai Zheng; 2005 Apr; 24(4):483-7. PubMed ID: 15820075
[TBL] [Abstract][Full Text] [Related]
13. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
15. The Herb-Drug Pharmacokinetic Interaction of 5-Fluorouracil and Its Metabolite 5-Fluoro-5,6-Dihydrouracil with a Traditional Chinese Medicine in Rats.
Liu JH; Cheng YY; Hsieh CH; Tsai TH
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29295501
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies.
Ochoa L; Hurwitz HI; Wilding G; Cohen D; Thomas JP; Schwartz G; Monroe P; Petros WP; Ertel VP; Hsieh A; Hoffman C; Drengler R; Magnum S; Rowinsky EK
Ann Oncol; 2000 Oct; 11(10):1313-22. PubMed ID: 11106122
[TBL] [Abstract][Full Text] [Related]
17. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
[TBL] [Abstract][Full Text] [Related]
18. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer.
Gusella M; Crepaldi G; Barile C; Bononi A; Menon D; Toso S; Scapoli D; Stievano L; Ferrazzi E; Grigoletto F; Ferrari M; Padrini R
Ann Oncol; 2006 Nov; 17(11):1656-60. PubMed ID: 16968871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]